Mainstream

Arcturus signals extended cash runway into 2028 with strategic shift toward cf and otc mrna therapeutics

Arcturus signals extended cash runway into 2028 with strategic shift toward CF and OTC mRNA therapeutics

Arcturus signals extended cash runway into 2028 with strategic shift toward CF and OTC mRNA therapeutics

Post ContentarctRead More

You might also be interested in reading Relx surges to record high amid growing demand for its AI-powered products.

May 12, 2025
In Mainstream